These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 24392295

  • 1. Effect of switching recombinant human growth hormone: Comparative analysis of phase 3 clinical data.
    Romer T, Zabransky M, Walczak M, Szalecki M, Balser S.
    Biol Ther; 2011; 1(1):5. PubMed ID: 24392295
    [Abstract] [Full Text] [Related]

  • 2. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study.
    Romer T, Saenger P, Peter F, Walczak M, Le Bouc Y, Khan-Boluki J, Berghout A.
    Horm Res; 2009; 72(6):359-69. PubMed ID: 19844125
    [Abstract] [Full Text] [Related]

  • 3. Switching to Omnitrope(®) from Other Recombinant Human Growth Hormone Therapies: A Retrospective Study in an Integrated Healthcare System.
    Rashid N, Saenger P, Wu YL, Woehling H, Frankel M, Lifshitz F, Muenzberg M, Rapaport R.
    Biol Ther; 2014 Dec; 4(1-2):27-39. PubMed ID: 25096555
    [Abstract] [Full Text] [Related]

  • 4. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L, Luo XP, Du ML, Ma HM, Gong CX, Li YC, Shen SX, Zhao ZH, Liang L, Dong GP, Yan CY, Du HW.
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution.
    Romer T, Peter F, Saenger P, Starzyk J, Koehler B, Korman E, Walczak M, Wasik R, Ginalska-Malinowska M, Solyom E, Berghout A.
    J Endocrinol Invest; 2007 Jan; 30(7):578-89. PubMed ID: 17848841
    [Abstract] [Full Text] [Related]

  • 7. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
    Pfäffle R, Bidlingmaier M, Kreitschmann-Andermahr I, Land C, Partsch CJ, Schwab KO, Sommer H, Backeljauw P, Kanumakala S, Loche S, Zouater H, Strasburger CJ.
    Horm Res Paediatr; 2020 Jan; 93(3):154-163. PubMed ID: 32814319
    [Abstract] [Full Text] [Related]

  • 8. Two-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
    Schwarz HP, Walczak M, Birkholz-Walerzak D, Szalecki M, Nanu M, Woehling H, Schuck E.
    Adv Ther; 2016 Mar; 33(3):423-34. PubMed ID: 26886776
    [Abstract] [Full Text] [Related]

  • 9. PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope® (somatropin) treatment in children: update on the United States cohort.
    Backeljauw P, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K.
    J Pediatr Endocrinol Metab; 2021 Apr 27; 34(4):431-440. PubMed ID: 33647196
    [Abstract] [Full Text] [Related]

  • 10. Long-term safety and efficacy of the recombinant human growth hormone Omnitrope® in the treatment of Spanish growth hormone deficient children: results of a phase III study.
    López-Siguero J, Borrás Pérez MV, Balser S, Khan-Boluki J.
    Adv Ther; 2011 Oct 27; 28(10):879-93. PubMed ID: 21948492
    [Abstract] [Full Text] [Related]

  • 11. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
    Ballerini MG, Braslavsky D, Scaglia PA, Keselman A, Rodríguez ME, Martínez A, Freire AV, Domené HM, Jasper HG, Bergadá I, Ropelato MG.
    Horm Res Paediatr; 2017 Oct 27; 88(5):354-363. PubMed ID: 28926833
    [Abstract] [Full Text] [Related]

  • 12. A follow-up study to monitor adult height among Spanish children with growth hormone deficiency who received biosimilar human recombinant growth hormone (Omnitrope®) during a phase III clinical trial.
    Borrás Pérez V, López-Siguero JP, Martínez G, Corripio R, Fernández JM, Labarta JI, Ferrer M, Cabrinety N, Prieto P, Ramón-Krauel M, Bosch J, Espino R, Palla Garcia M, Rebollo FJ.
    Adv Ther; 2015 Feb 27; 32(2):148-56. PubMed ID: 25667132
    [Abstract] [Full Text] [Related]

  • 13. Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin.
    Fuhr U, Tuculanu D, Berghout A, Balser S, Schwebig A, Saenger P.
    Eur J Endocrinol; 2010 Jun 27; 162(6):1051-8. PubMed ID: 20332125
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. One-Year Data from a Long-Term Phase IV Study of Recombinant Human Growth Hormone in Short Children Born Small for Gestational Age.
    Schwarz HP, Birkholz-Walerzak D, Szalecki M, Walczak M, Galesanu C, Metreveli D, Khan-Boluki J, Schuck E.
    Biol Ther; 2014 Dec 27; 4(1-2):1-13. PubMed ID: 24676989
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Short-term efficacy and safety of a lower dose of polyethylene glycol recombinant human growth hormone in children with growth hormone deficiency: A randomized, dose-comparison study.
    Jiang Z, Chen X, Dong G, Lou Y, Zhang J, Cheng X, Pan J, Liao W, Wu J, Huang X, Jin X, Liu D, Zeng T, Zhu S, Dong Q, Luo X, Lan D, Cao L, Zhang X, Liu J, Dai M, Zhang M, Liu L, Dong J, Zhao D, Ni S, Fu J.
    Front Pharmacol; 2022 Dec 27; 13():955809. PubMed ID: 36034802
    [Abstract] [Full Text] [Related]

  • 18. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
    Ranke MB, Traunecker R, Martin DD, Schweizer R, Schwarze CP, Wollmann HA, Binder G.
    Horm Res; 2005 Dec 27; 64(2):68-76. PubMed ID: 16113581
    [Abstract] [Full Text] [Related]

  • 19. Safety and effectiveness of Omnitrope® in patients with growth hormone deficiency: snapshot analysis of PATRO Adults study in the Italian population.
    Arosio M, Arnaldi G, Gasco V, Giavoli C, Puxeddu E, Vettor R, Ambrosio MR, Gallinari P, Zouater H, Fedeli P, Ferone D.
    J Endocrinol Invest; 2021 Feb 27; 44(2):327-337. PubMed ID: 32507990
    [Abstract] [Full Text] [Related]

  • 20. Long-term safety and efficacy of Omnitrope® in adults with growth hormone deficiency: Italian interim analysis of the PATRO Adults study.
    Ferone D, Profka E, Gasco V, Ambrosio MR, Colao A, Di Somma C, Puxeddu E, Arnaldi G, Pagano C, Zecchi E, Pietropoli A, Beck-Peccoz P.
    J Endocrinol Invest; 2017 Jun 27; 40(6):669-678. PubMed ID: 28161880
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.